Adverse Events in the Treatment of Multidrug-Resistant Tuberculosis: Results From the DOTS-Plus Initiative

Int J Tuberc Lung Dis. 2004 Nov;8(11):1382-4.

Abstract

Adverse events associated with second-line drugs have been mentioned as obstacles in the management of multidrug-resistant tuberculosis (MDR-TB). Data on adverse events were collected from five DOTS-Plus sites in Estonia, Latvia, Peru (Lima), the Philippines (Manila) and the Russian Federation (Tomsk Oblast). The results show that among 818 patients enrolled on MDR-TB treatment only 2% of patients stopped treatment, but 30% required removal of the suspected drug(s) from the regimen due to adverse events. The study shows that adverse events are manageable in the treatment of MDR-TB in resource-limited settings provided that standard management strategies are applied.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, Non-P.H.S.

MeSH terms

  • Adult
  • Antitubercular Agents / adverse effects*
  • Directly Observed Therapy*
  • Estonia
  • Female
  • Humans
  • Latvia
  • Male
  • Medication Adherence
  • Peru
  • Philippines
  • Retrospective Studies
  • Russia
  • Treatment Outcome
  • Tuberculosis, Multidrug-Resistant / drug therapy*

Substances

  • Antitubercular Agents